Medical supply chain professionals say they’re seeing a rise in the number of medical products containing harmful chemicals.
The chemicals, called antimicrobials, are being sold in hospitals, pharmacies and health-care facilities in the United States.
They include those sold by U.S. specialty drug makers and specialty retailers like Walmart, Walgreens and Rite Aid, among others.
They’re also found in some drugs made by specialty pharmaceutical companies, including Avon Products, Pfizer, Johnson & Johnson, AstraZeneca and Johnson & Johnson.
They can also be found in other products sold by hospitals, hospitals’ purchasing partners, health- care providers, pharmacies, retail stores and health insurance companies.
In addition, antimicrobial products made by companies like Gilead Sciences and McKesson are being distributed in hospitals across the country.
Gilead said in a statement that it has stopped making and distributing the products and is reviewing all of its manufacturing facilities.
It did not respond to a request for comment from The Associated Press.
McKesson did not immediately respond to messages left for a company spokesman.
The U.K.-based pharmacy giant said in an email that it stopped selling its Gileader-Smith products in October.
Gillham &.; Bacon said it has discontinued manufacturing its Gileser-Smith antimicrobial soap and detergent products.
The company also stopped making its other antimicrobial product, Neosporin, in August.
Kellogg &., which makes the anti-bacterial Soap and Nail Cloth, said it stopped making Neospermin and is considering ending distribution of Neosperin to other health care providers.
The product is also available through retailers such as Walgies and Rite-Aid, the pharmacy giant’s parent company.
“McKinseys products are now being made in the U.P.A. facility,” the company said in the statement.
“This is in response to regulatory changes that have taken place at the U of T and are in line with our long-term strategic goals.”
The Associated Press has been working with the UofT and other health-system stakeholders to determine how many of the antimicrobial agents are being used.
It also is trying to find out how many people are using them.
In a statement, the U-T said it is taking steps to reduce antimicrobial use.
“We have been working closely with the government and the industry to identify the sources of antimicrobial waste in the health-providers supply chain,” it said.
The government has made efforts to encourage antimicrobial alternatives.
In recent years, the pharmaceutical industry has been grappling with the emergence of a growing body of research that suggests antimicrobial ingredients in products such as toothpaste and toothbrushes are dangerous.
It has been difficult for health- system providers to identify and monitor the use of antimicrobal agents in their own supply chains.More: